The most striking example of this trend is a study by Choudhury and colleagues on targeted antimicrobial therapy against Fusobacterium nucleatum, an anaerobic bacterium that has attracted intense attention for its association with colorectal cancer. Rather than deploying broad-spectrum antibiotics that devastate beneficial gut flora, the team engineered Lactococcus lactis, a harmless dairy bacterium widely used in food fermentation, to deliver guided antimicrobial peptides, or gAMPs. These short, designed molecules carry built-in specificity: they are structured to bind and disrupt the membranes of the target pathogen while sparing closely related commensal species. In simulated gut environments, the engineered delivery system achieved selective inhibition of F. nucleatum with reduced toxicity and, crucially, preserved the overall diversity of the microbial community. That last point matters enormously. One of the persistent failures of conventional antibiotic treatment in the gut is collateral damage to the microbiota, which can open the door to opportunistic pathogens such as Clostridioides difficile. A living therapeutic that carries its own targeting logic, and that can be dosed as a probiotic, represents a fundamentally different pharmacological paradigm. The work also hints at a future in which engineered bacterial vectors are programmed to sense disease-associated niches and respond with localized, self-limiting antimicrobial activity, a vision the authors frame as a next-generation alternative to small-molecule drugs.

The probiotic theme continued to dominate engagement in a second area: immunometabolism and chronic inflammatory disease. Wang and colleagues reported that Lactobacillus paragasseri strain LG-1 modulates metabolism, restores microbiota balance, and reduces inflammation in chronic spontaneous urticaria, a debilitating skin condition characterized by recurrent hives and driven by dysregulated immune signalling. The study traced the strain’s effects through immune pathway regulation, connecting microbial metabolites to the suppression of the histamine-driven flare responses that define the disease. What makes this line of research compelling is its mechanistic depth: rather than simply documenting an association between a strain and symptom relief, the authors mapped the metabolic and immunological intermediaries through which the probiotic acts. Interest in therapeutic microbes is also driving parallel work on delivery technology. A study by Zhu and colleagues examined probiotic microencapsulation, the practice of wrapping live cells in protective polymer shells that shield them from stomach acid and release them at targeted sites in the intestine. Encapsulation addresses the central technical weakness of oral probiotics, poor viability during gastric transit, and its refinement is a prerequisite for the kind of personalized, strain-specific microbial therapeutics that the urticaria study points toward. Together these papers suggest that the probiotic field is maturing from a genre of dietary supplements into a discipline of rationally designed, encapsulated, and mechanistically characterized living medicines.

Followers engaged just as strongly with work that pointed off-world. Vidal and colleagues explored how Earth’s deep subsurface microbiome can inform the search for extraterrestrial life. Microorganisms thriving in extreme, low-energy environments kilometres beneath the planet’s surface, fractured rock aquifers where chemical energy, not sunlight, fuels life, provide the best available analogues for potential habitats on Mars and on icy moons such as Europa and Enceladus. The logic is straightforward: if life exists elsewhere in the solar system, it almost certainly survives under energy limitation, in dark, chemically fed ecosystems resembling Earth’s deep biosphere. The study’s conclusions carry practical weight for mission design. Extraterrestrial life, the authors argue, is likely to be slow-growing and metabolically sparse, which means it will be extraordinarily difficult to detect with conventional instruments. Populations that double on timescales of centuries or millennia leave faint chemical footprints, so biosignature identification must be refined, and detection technologies must become orders of magnitude more sensitive. The subsurface microbiome, in other words, is not just a biological curiosity; it is a training dataset for the instruments that may one day answer whether we are alone. The astronomical engagement numbers for this study suggest that astrobiology’s appeal remains unmatched, but its inclusion among the top-followed papers also reflects a genuine methodological convergence between geomicrobiology and planetary science.

Back on the surface, sustainable agriculture emerged as another follower favourite, centred on microbial volatile organic compounds. A review by Belt and colleagues examined VOCs as promising alternatives to chemical pesticides. These small, airborne molecules, produced naturally by beneficial rhizosphere bacteria and fungi, can inhibit plant pathogens at a distance, induce systemic resistance within plant tissues, and promote growth, all without leaving the toxic residues associated with synthetic agrochemicals. The technical promise is real, but so are the obstacles. Translating laboratory findings into field applications has proven difficult because VOC activity depends on soil type, moisture, temperature, and the composition of the resident microbial community, variables that fluctuate wildly outside the growth chamber. Detection is a further bottleneck: many bioactive volatiles are produced at nanomolar concentrations and require sophisticated analytical techniques such as gas chromatography-mass spectrometry to identify and quantify. The authors argue that future progress will depend on integrating ecological complexity into experimental design, moving beyond single-strain, single-pathogen assays toward multi-species systems that resemble real soil. The same momentum is visible in a complementary review by Xiong and colleagues from the group of Brajesh Singh, which situates these advances within the rapidly expanding field of soil microbiome research and its application to crop health. Together the two papers mark a shift in agricultural microbiology from description toward engineering: the goal is no longer merely to catalogue which microbes live around roots, but to deploy them, deliberately and predictably, as part of integrated pest management.

At the level of intracellular architecture, two further studies drew heavy engagement for what they reveal about bacterial organization and gene regulation. Chang and colleagues investigated bacterial microcompartments in Salmonella, protein-shelled organelles that sequester specific enzymatic pathways from the rest of the cytoplasm. By constructing engineered hybrid microcompartments, the team demonstrated that these structures can be used to reorganize metabolic pathways, co-locating enzymes and substrates in ways that improve flux and reduce unwanted cross-reactions. The implications extend into synthetic biology: BMCs are essentially programmable nanoreactors, and understanding how their shells, targeting sequences, and encapsulated enzymes assemble opens the door to designing custom metabolic modules inside industrially relevant bacteria. Complementing this structural perspective, Fernández-Fernández and colleagues examined how variability in promoter regions of epigenetically regulated operons enables bacteria to fine-tune gene expression and adapt rapidly to environmental pressures. Populations of bacteria, the study shows, maintain stochastic diversity in promoter architecture, generating a spectrum of expression states within a single clone; when conditions change, the individuals best suited to the new environment dominate. This bet-hedging strategy is a cornerstone of bacterial resilience, and deciphering its molecular mechanisms has direct consequences for one of the gravest threats in modern medicine. As a commentary by Brüssow emphasized, antibiotic resistance is expected to become the leading global cause of death worldwide by 2050, and understanding the regulatory logic that lets pathogens survive stress is essential to developing strategies that disarm rather than merely kill them.

Industrial biotechnology supplied the remaining high-engagement stories, and both point toward cheaper, faster, greener manufacturing. Matamouros and colleagues described a high-throughput platform for signal peptide screening in Corynebacterium glutamicum, the workhorse bacterium behind much of the world’s industrial amino acid production. Signal peptides are the short N-terminal sequences that direct proteins to the secretion machinery, and choosing the right one for a given recombinant protein has traditionally been a slow, empirical exercise. The new platform allows thousands of signal peptide-protein combinations to be tested in parallel, identifying optimal secretion routes in days rather than months. Because secreted proteins are far easier and cheaper to purify than intracellular ones, the platform directly reduces development time and manufacturing cost for enzymes, therapeutic proteins, and industrial biocatalysts. On the sustainability front, Zini and colleagues tackled one of the field’s enduring problems: producing bioplastics without sterile, energy-intensive fermentation infrastructure. Their solution was a hybrid microbiome approach, integrating engineered cyanobacteria that photosynthetically fix carbon into biodegradable plastic precursors within natural microbial communities. The resulting consortia proved robust under scalable, non-sterile conditions, sidestepping the contamination vulnerabilities that make conventional pure-culture fermentation expensive. If such systems can be scaled further, they offer a route to plastics production that runs on sunlight and mixed microbial communities rather than refined sugar feedstocks and aseptic facilities.

Taken together, the follower-selected collection tells a coherent story about where microbiology is heading. The most resonant work of the period shares three characteristics: it is mechanism-rich, connecting molecular detail to physiological outcomes; it is application-oriented, targeting cancer-associated pathogens, chronic inflammatory disease, crop protection, and industrial production; and it is engineered, whether the object being engineered is a probiotic genome, a protein shell, a signal peptide library, or an entire synthetic-natural consortium. The editorial exercise itself, letting social-media engagement guide a review of the field, is also a signal. Scientific communities are no longer passive recipients of published knowledge; they are active curators, and their collective attention is proving to be a surprisingly reliable compass for the discipline’s future. As microbial innovation accelerates across medicine, agriculture, energy, and industry, the studies that rise to the top of the feed suggest that the field’s centre of gravity is shifting from understanding microbes to building with them, and that the solutions to some of today’s most pressing global challenges may well be microscopic, living, and designed.

Biological cells rely heavily on membranes punctuated by pores and channels to maintain their internal environment, facilitate selective exchange of molecules, and orchestrate complex biochemical cascades. These functions hinge on the collective and dynamic interactions among molecular components, ensuring adaptability and responsiveness. The team at Stuttgart employed DNA nanotechnology to fabricate dynamic nanopores capable of mutual interaction within a lipid bilayer. This construct serves as a microreactor where molecular transport can be regulated in real time, echoing the complex regulatory networks seen in nature.

The core innovation rests on coupling two distinct DNA-based nanopores embedded within an artificial membrane, which communicate through membrane dynamics. Activation of the first nanopore initiates conformational and organizational changes that trigger the formation of the second pore type. This reciprocal interaction enables fine-tuning of membrane permeability and confinement conditions, thereby establishing a programmable environment for orchestrated biochemical reactions and molecular trafficking. The approach bridges the gap between static synthetic membrane models and dynamic cellular behaviors.

Professor Laura Na Liu, who leads the 2nd Physics Institute at the University of Stuttgart, elaborates that this system exemplifies a new paradigm in synthetic cell design: moving beyond mere structural fabrication to engineering dynamic, interactive, and functionally coupled components. The spatial and temporal coordination of pore formation and activity underscores the utility of DNA nanotechnology not only as a material for nanoscale assembly but increasingly as a medium to program and regulate multi-component synthetic systems.

At the heart of this platform lies the principle of collective organization—biological complexity frequently emerges from networks of interacting units rather than isolated entities. Cellular collective behavior stems from pervasive communication, feedback loops, and regulation across scales. This synthetic system embodies these principles by allowing nanopores to respond to and influence each other’s states via the membrane milieu, thus recapitulating aspects of biological regulatory dynamics in a minimal artificial setting.

By integrating membrane dynamics with programmable DNA nanostructures, this research introduces a versatile bottom-up strategy to create self-regulating synthetic modules. The membrane compartment serves as a dynamic reaction chamber where membrane permeability can be modulated to deliver reactants and substrates in a defined sequence, enabling control over reaction kinetics and spatial confinement. Such precision is challenging to achieve in traditional synthetic or cell-free biochemical platforms but is crucial for mimicking cellular metabolism and signaling.

Experimental demonstrations highlighted the platform’s capability to mediate cascades of enzyme-driven transformations resembling cellular metabolic pathways. The microreactor also facilitated actin polymerization and bundling within its confined space, recapitulating cytoskeleton-like structural organization. Moreover, the system supported controlled transcription of RNA sequences using the Spinach RNA aptamer in a cell-free manner, alongside the confined nucleation and growth of three-dimensional DNA crystals, showcasing its breadth and versatility in handling diverse biochemical processes.

Stephan Nussberger, head of the Biophysics Division at the Institute for Biomaterials and Biomolecular Systems at the University of Stuttgart, emphasizes the transformative potential of this technology. The dynamic, programmable nature of this platform opens avenues for synthetic biochemistry capable of executing complex, multistep reactions autonomously. Applications could range from tailored drug synthesis and biosensing to artificial cells that perform decision-making tasks based on environmental cues, heralding a new era in biotechnology and synthetic life engineering.

DNA nanotechnology was crucial to the success of this work. Unlike traditional use of DNA as genetic material, this field capitalizes on DNA’s programmable nature to engineer nanoscale devices and architectures. The Liu research group has been at the forefront, previously developing DNA-based dynamic assemblies on cellular membranes, but this study marks a significant advance towards systems capable of collective behavior and communication akin to living cells.

Looking forward, the researchers underscore that the future lies in constructing synthetic systems where components do not simply exist independently but interact, communicate, and collectively organize functions. This microreactor exemplifies such a progression, steering synthetic biology towards creating functional artificial cells that can dynamically adapt, respond, and self-regulate, much like natural biological entities.

This landmark study, published in Nature Chemistry, represents a pivotal advancement not only in synthetic cell research but also in how molecular engineering and materials science intersect with fundamental biological principles. The “double-necked synthetic cell microreactor” stands as a compelling model for harnessing dynamic molecular interactions within artificial membranes, promising transformative impacts across biotechnology, medicine, and nanotechnology.

In summary, the creation and functional demonstration of this double-necked synthetic cell microreactor herald a new frontier in programmable synthetic biology. By harnessing the intrinsic programmability of DNA and embedding this within a dynamic membrane context, researchers have charted a course towards artificial cells and biochemical systems capable of sophisticated molecular communication and reaction orchestration. This opens myriad possibilities for synthetic life forms engineered from the bottom up, blurring the boundaries between biology and technology.

Subject of Research: Development of a dynamic synthetic cell microreactor using interacting DNA nanopores to mimic biological membrane functions and programmable biochemical reactions.

Article Title: Breakthrough in synthetic cell research

News Publication Date: 15 May 2026

Web References:
https://doi.org/10.1038/s41557-026-02124-7

References:
Sisi Fan, Longjiang Ding, Benjamin Renz, Allen P. Liu, Thomas Speck, Hao Yan, Stephan Nussberger & Laura Na Liu. “A synthetic cell microreactor with two types of interacting dynamic DNA-based pores.” Nature Chemistry (2026). DOI: 10.1038/s41557-026-02124-7

Image Credits: University of Stuttgart, 2nd Physics Institute

Keywords

Synthetic cell, DNA nanotechnology, nanopores, membrane dynamics, programmable biochemistry, molecular transport, biochemical microreactor, dynamic regulation, enzyme cascades, cytoskeletal mimicry, artificial compartments, collective behavior

Optical regulation of proteins has long been heralded as a central pillar in the study and engineering of complex biological systems. Previously, such control depended heavily on natural photoreceptors or chemo-optogenetic designs that repurposed existing protein–ligand pairs. While these approaches facilitated many groundbreaking discoveries, their utility is inherently constrained by the fixed photochemistry and limited modularity of natural components. The new methodology flips the paradigm: rather than tweaking nature’s templates, it custom-builds the photoswitches with predetermined light-responsive characteristics and then isolates matching artificial protein binders using mRNA display technology — a tailored synthetic pair born de novo from design principles rather than evolution.

At the heart of this innovation lies the rational design of synthetic photoswitch molecules. These small molecules are engineered with precision to exhibit defined photoisomerization behaviors upon illumination at specific wavelengths, allowing researchers to dictate binding affinity changes strictly regulated by light exposure. This level of control surpasses what is achievable with natural chromophores, offering not only reversibility but also tunable kinetics and duration of action. By constructing these molecules from the ground up, the authors provide a versatile platform to modulate conformational states on demand, leading to unprecedented dynamic regulation of cellular proteins.

Complementing the synthetic photoswitch design is the utilization of mRNA display, a powerful in vitro selection technique that enables the screening of vast libraries of artificial proteins for binding specificity toward target molecules. Through iterative selection cycles, the team identified protein binders with high affinity that bind selectively to one photoisomeric form of the synthetic molecule over the other. Such precise discrimination ensures that light can act as an external switch to toggle the protein-binder interaction, transforming the chemo-optogenetic system into a sophisticated light-responsive module with programmable functions.

This dual innovation – the tailored photoswitch and the mRNA display-selected binding protein – culminates in artificial photoswitch-binder pairs that act as modular, plug-and-play devices. The researchers demonstrated the platform’s broad applicability by integrating these pairs into complex mammalian cellular networks. For instance, they engineered systems enabling optical control over kinase signaling pathways, lipid metabolism, G-protein-coupled receptor (GPCR) activity, gene expression modulation, and even differentiation programs in stem-cell models. These successes underscore the platform’s capability to interrogate and engineer cell behavior with unparalleled spatiotemporal precision.

One of the most compelling features of these de novo chemo-optogenetic tools is their programmable regulatory modes. By simply adjusting light inputs—wavelength, intensity, duration—the system can be tuned for sustained, reversible, or repeated control over target protein functions, dramatically enhancing the versatility for experimental and therapeutic use. This precision addresses critical demands in understanding transient versus long-lasting signaling events, enabling the dissection of cellular dynamics with unprecedented clarity.

The engineering of completely artificial photoswitch–protein binder pairs alleviates many restrictions that natural systems impose. Natural photoreceptors exhibit inherent structural complexity, limited binding interfaces for engineering, and often undesired basal activity that complicates experimental outcomes. Similarly, natural chemo-optogenetic ligand–protein pairs frequently suffer from suboptimal kinetics and phototoxicity issues. The newly reported framework sidesteps these pitfalls by enabling finely tunable molecular properties and modularity, affording researchers a highly customizable platform adaptable to diverse biological contexts.

Moreover, the scalability inherent to mRNA display technology allows rapid discovery of binding proteins tailored to varying synthetic photoswitch chemistries. This means that as new photoswitches with distinct spectral and kinetic profiles are developed, corresponding binders can be selected, expanding the chemo-optogenetic repertoire continuously. The modular bottom-up fashion of design significantly accelerates innovation cycles compared to laborious modifications of existing natural components.

Beyond fundamental research, the authors envision far-reaching applications in biomedical sciences and therapeutic interventions. Precise optical control of protein functions in situ could enable spatiotemporal regulation of signaling cascades implicated in diseases such as cancer, neurodegeneration, and metabolic disorders. Furthermore, the ability to program distinct regulatory modes by light offers a promising avenue for developing next-generation cell-based therapies where patient safety and reversible control remain paramount.

Technical intricacies of the synthetic photoswitch design involved optimizing molecular scaffolds for robust photoisomerization with minimal off-target effects and maximizing binding site accessibility. The artificial protein binders were meticulously selected to achieve nanomolar affinity differentials between photoisomer states. The synergy of molecular design and selection yields pairs exhibiting switching fidelity and stability compatible with cellular environments—a feat not trivial given the complexity and molecular crowding in living cells.

Experimental validations encompassed a suite of cellular assays deploying the chemo-optogenetic pairs to manipulate key proteins in signaling pathways. Using light to toggle kinase activity in engineered mammalian cells resulted in downstream changes in phosphorylation states detectable by phospho-specific antibodies, confirming reversible modulation. Similarly, optical control of lipid signaling enzymes demonstrated the ability to spatially pattern lipid modifications inside the membrane, verified by fluorescence lipid reporters. The functionality extended to control of GPCRs—key drug targets—demonstrating potential for precise neurochemical modulation.

Intriguingly, when applied to gene expression circuits, the chemo-optogenetic pairs allowed rapid induction and suppression of transcription in response to short light pulses. This opens avenues for optically programmable gene therapies where expression levels can be dynamically adjusted without genomic modifications. Additionally, in stem cell differentiation models, temporal patterns of light exposure orchestrated fate transitions, showcasing potential in regenerative medicine.

The integrated platform thus represents a new class of chemo-optogenetic reagents marrying synthetic chemistry with protein engineering. This marriage fosters an unprecedented level of control and modularity in optical protein manipulation, fundamentally expanding the toolkit available to biological researchers. It invites a future where dynamic, reversible, and programmable protein activity control can be customized down to the molecular level, transforming both lab-based investigations and clinical strategies.

This study sets a high bar for future optogenetic tool development by demonstrating that starting from synthetic molecular design, rather than natural systems, can yield highly functional and versatile chemo-optogenetic devices. It underscores the importance of interdisciplinary approaches combining rational chemical design, protein engineering, and cutting-edge display technologies to surmount the limitations of traditional biological tools.

The implications of this work will likely ripple across multiple fields—cell biology, synthetic biology, pharmacology, and beyond. It empowers researchers to interrogate cellular functions with light in an unprecedented manner while providing an enabling technology platform poised to drive innovations in biomedical applications where precise, tunable protein control is critical.

In closing, the de novo chemo-optogenetic framework revealed by Miyazaki and colleagues not only provides a novel technology for biological research but also exemplifies the transformative potential of rational molecular engineering combined with directed protein evolution. As the chemo-optogenetic toolkit expands and diversifies, it promises to illuminate complex cellular processes like never before, potentially catalyzing novel therapies and breakthroughs in our understanding of life at the molecular level.

Subject of Research: Development of de novo chemo-optogenetic tools via synthetic photoswitch design and artificial protein binder selection for precise optical control of cellular proteins.

Article Title: De novo chemo-optogenetics through the rational design of photoresponsive molecules and selection of their artificial protein binding pairs.

Article References:
Miyazaki, T., Fujino, T., Yoshii, T. et al. De novo chemo-optogenetics through the rational design of photoresponsive molecules and selection of their artificial protein binding pairs. Nat. Chem. (2026). https://doi.org/10.1038/s41557-026-02121-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41557-026-02121-w

At its core, the newly introduced approach addresses a longstanding bottleneck in synthetic biology. While generative modeling of DNA, RNA, and protein sequences has advanced immensely, the physical realization of these designs remained prohibitively costly and logistically challenging. Traditional DNA synthesis methods, constrained by their linear, deterministic nature, struggle to scale without astronomical financial and time investments. This breakthrough circumvents these limitations by embedding generative sampling mechanisms directly into wet lab procedures. In doing so, the researchers effectively transpose the stochastic sampling processes of computational models into the biochemical realm through controlled chemical reactions.

Central to the approach is the concept of manufacturing-aware generative modeling. Unlike conventional generative models that operate purely within computational frameworks, these models are cognizant of synthesis constraints and capabilities from the outset. This fusion ensures that the sequences produced not only meet biological criteria for functionality and diversity but are also optimized for manufacturability. By marrying algorithmic sampling with parallelized DNA oligosynthesis, the method realizes magnitudes of throughput—approaching a staggering 10^16 unique DNA sequences synthesized in a single operational timeframe.

The practical validation of this approach was demonstrated through its application to human antibody engineering. Antibodies, with their immense therapeutic potential and structural complexity, represent an ideal proving ground. Generating an expansive library of single-chain variable fragment antibodies (scFvs), the team synthesized variants exhibiting diversity and biological realism equivalent to the outputs of state-of-the-art protein language models. This parity underscores the method’s robustness in maintaining the intricate balance of sequences necessary for functional antibody expression.

Verification of the designed DNA libraries employed high-throughput sequencing techniques, ensuring fidelity between intended generative outputs and empirical realizations. Importantly, the researchers extended their approach beyond synthetic validation. They transfected human cell lines with the synthesized scFv libraries, achieving translation and functional expression. This critical step confirmed that the physical DNA not only faithfully replicated computational designs but also retained biological activity—a testament to the meticulous integration of design and manufacturing parameters.

Perhaps most striking is the subsequent application of these expressed antibodies in multiplexed screens against human leukocyte antigen (HLA)-presented intracellular proteins. This high-throughput screening strategy unveiled potential leads for chimeric antigen receptors (CARs), offering transformative possibilities for immunotherapy. By streamlining the design-to-expression-to-screening pipeline at an industrial scale, the researchers lay the groundwork for accelerated therapeutic discovery and development, shortening timelines that historically span years.

The versatility of the method was further corroborated through its application to other biological targets. Generative models of Taq polymerase and the HLA-presented peptidome were physically instantiated, again achieving petascale DNA synthesis with comparable efficacy. This breadth of applicability indicates that manufacturing-aware generative synthesis is not confined to specific protein classes but can generalize across diverse biomolecular families, signaling broad implications for synthetic biology, diagnostics, and beyond.

Underpinning this revolution is a sophisticated interplay between computational and chemical engineering disciplines. The generative model’s stochastic sampling algorithms are emulated in the lab by precisely tuned chemical reactions during oligonucleotide synthesis. Instead of sequential, deterministic DNA strand construction, this methodology introduces controlled stochasticity that mirrors the probabilistic nature of computational models. This innovation enables parallelized synthesis pathways that dramatically accelerate throughput while maintaining sequence diversity and design fidelity.

Such a paradigm shift has profound implications for the future of biomolecular design. By physically embodying generative models, researchers no longer remain confined to digital sequence libraries but can access vast, tangible molecular libraries for experimental interrogation. This capability transforms exploratory biology, permitting rapid hypothesis testing and iterative optimization in physical systems, which is critical for discovering novel therapeutics and understanding complex biomolecular interactions.

Moreover, this approach aligns seamlessly with advancements in high-throughput sequencing and screening technologies, forming an integrated ecosystem for synthetic biology. Large-scale sequencing validates the integrity of vast DNA libraries while multiplexed protein binding assays and functional screens elucidate biological relevance. This interconnected pipeline accelerates the transition from computational models to real-world applications, enhancing reproducibility and expanding the design space for synthetic biomolecules.

From a commercial perspective, manufacturing-aware generative DNA synthesis promises to reduce costs, timeframes, and resource burdens traditionally associated with large-scale DNA library production. Companies engaged in antibody discovery, vaccine development, and enzyme engineering stand to benefit immensely from this innovation. By enabling massive sequence diversities within a single synthesis batch, the method facilitates the rapid identification of lead candidates, expediting drug development cycles and personalized medicine initiatives.

The futuristic vision encapsulated by this technology also hints at potential integration with automated laboratory workflows and robotic synthesis platforms. Such synergies could lead to fully autonomous design-build-test cycles for biomolecules, ushering in a new paradigm of synthetic biology research empowered by artificial intelligence and molecular manufacturing capabilities.

Despite these dramatic advances, the method acknowledges inherent complexities in translating in silico models to biochemical reality. Ensuring synthesis fidelity, managing stochastic variability, and optimizing reaction conditions require tightly coupled interdisciplinary expertise. Continuous refinements in oligosynthesis chemistry, error correction protocols, and model calibration will be essential to fully realize the potential of manufacturing-aware generative synthesis on an even grander scale.

Looking forward, the field stands poised at the confluence of computational creativity and synthetic feasibility. By physically embedding machine learning models within chemical manufacturing pipelines, researchers have not only amplified the scale of DNA design synthesis but have also redefined the ethos of bioengineering. This pioneering work heralds a future where petascale libraries of designed biomolecules are routinely generated, validated, and harnessed for scientific and therapeutic breakthroughs, fundamentally reshaping our approach to biomolecular innovation.

In sum, this landmark study exemplifies the power of synthesis-aware generative modeling, vindicating a vision where complex biomolecular landscapes are not merely imagined but physically instantiated at scales previously thought unattainable. The amalgamation of AI-driven design and precision biochemical synthesis sets a new standard, transforming conceptual possibility into experimental reality and accelerating the pace at which biology can be engineered for humanity’s benefit.

Subject of Research: Generative modeling and large-scale DNA synthesis integrating machine learning with biochemical manufacturing.

Article Title: Manufacturing-aware generative models enable petascale synthesis of designed DNA.

Article References:
Weinstein, E.N., Gollub, M.G., Slabodkin, A. et al. Manufacturing-aware generative models enable petascale synthesis of designed DNA. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03020-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41587-026-03020-8

Evo 2 operates through unconstrained autoregressive generation, starting from partial genomic sequences and autonomously completing gene sequences with remarkable fidelity. Researchers tested Evo 2’s capability by prompting the model with 1,000 base pairs of upstream genomic context along with the initial 500 to 1,000 base pairs of a target gene. Their findings revealed that Evo 2 consistently outperforms Evo 1, achieving higher amino acid sequence recovery rates that improve with model scale. The 40-billion and 7-billion parameter versions of Evo 2 not only demonstrated superior gene completion but also maintained accuracy throughout sequences requiring long contextual understanding.

While Evo 2 excels broadly, its performance on viral genomes, particularly DNA from human viruses, remains suboptimal. This limitation was highlighted in tests showing essentially random sequence recovery in these cases, thereby naturally constraining the model’s capacity to generate human viral proteins accidentally or unconstrainedly. This specificity is notable since viruses pose unique sequence prediction challenges due to rapid mutation rates and diverse evolutionary pressures, offering an inherent safeguard in Evo 2’s design.

The scale of Evo 2’s generative prowess was dramatically displayed through its ability to replicate the entire human mitochondrial genome. The model generated over 250 unique 16-kilobase sequences prompted from human mitochondrial DNA fragments. These artificial mitochondrial genomes, when analyzed via the annotation toolkit MitoZ, showed the correct number and distribution of coding sequences (CDSs), transfer RNAs (tRNAs), and ribosomal RNAs (rRNAs), faithfully reproducing natural mitochondrial gene synteny and organization. There was notable sequence similarity with native mitochondrial genes, accompanied by appropriate codon usage patterns aligning closely with authentic human mitochondrial DNA.

Further structural validations employed AlphaFold to predict the 3D conformations of proteins generated by Evo 2 from these artificial mitochondrial sequences. Remarkably, many predicted proteins formed multimeric complexes structurally analogous to their natural counterparts, suggesting that Evo 2 can design protein-coding regions that potentially fold into biologically relevant structures. This structural fidelity is crucial for future applications aiming to produce functional biomolecules from computationally designed genomes.

Pushing the envelope on genomic scale, Evo 2 was tasked with generating prokaryotic genomes, focusing on Mycoplasma genitalium, a bacterial species with a minimal known genome of approximately 580 kilobases. By seeding the model with a 10.5-kilobase prompt from the reference genome, the researchers generated ten complete genome-length sequences. Annotations using Prodigal revealed that about 70% of the genes predicted in these synthetic genomes contained statistically significant Pfam domain hits, a substantial leap from Evo 1’s 18%. The distribution of gene lengths and predicted secondary protein structures closely mirrored those observed in natural M. genitalium proteins, suggesting that Evo 2 can faithfully reproduce minimalistic bacterial genome architecture.

In addition to prokaryotes, Evo 2’s genomic generation extended into eukaryotic complexity by generating sequences from Saccharomyces cerevisiae (baker’s yeast) chromosome III. Prompted with just 10.5 kilobases of native sequence, Evo 2 extrapolated to produce 330-kilobase sequences encompassing thousands of base pairs. These synthetic chromosomes included essential genetic elements such as tRNAs, promoters, and genes with authentic intronic structures, although feature densities like tRNA and gene counts were somewhat lower than in the native yeast genome. Despite this, the genes displayed length distributions akin to natural yeast proteins, with varying degrees of predicted structural similarity, underscoring Evo 2’s potential as a tool for complex eukaryotic genome reconstruction.

Evo 2’s ability to capture phylogenetic signals was also tested through tetranucleotide usage deviation (TUD) analyses, a metric commonly used to assess genomic relatedness. Synthetic sequences generated for S. cerevisiae demonstrated a correlation in TUD patterns with native genomes, an effect more pronounced in larger Evo 2 models. This phylogenetic fidelity suggests cataloging and replicating evolutionary constraints at the DNA sequence level, hinting at Evo 2’s use in studying genome evolution and species diversification computationally.

Despite these remarkable in silico successes, the researchers acknowledge critical limitations. Most notably, the computational metrics and annotations do not guarantee that Evo 2-generated genomes are functionally viable or capable of autonomous replication. Essential genomic elements, such as undetected regulatory sequences or critical but unannotated genes, may be missing. Realizing fully functional synthetic genomes will require extensive experimental validation and iterative refinement through sophisticated biotechnological platforms.

The evolutionary insights gleaned from Evo 2’s generative capabilities extend beyond mere recreation of known genomes. The model exhibits the capacity to diversify sequence compositions while maintaining structural and functional coherence, as evidenced by AlphaFold structural predictions showing protein variants with high structural similarity but diverse amino acid arrangements. Such findings raise exciting prospects for directed protein evolution and synthetic biology, where novel protein scaffolds with desired functions can be computationally designed.

Evo 2’s genomic generation spans the tree of life, establishing a comprehensive foundational platform for genome engineering. It holds vast potential in biotechnology, from constructing minimal synthetic cells and organelles to enabling precision gene therapies and the design of novel biomolecules. Furthermore, by harnessing Evo 2 for genome synthesis, researchers can systematically dissect the grammar of genomic information, unraveling hidden rules governing biological sequence function and evolution.

Importantly, Evo 2 also illustrates the power of scaling in artificial intelligence models applied to biological data. Larger parameter models consistently outperform smaller ones in sequence recovery and genome completeness, revealing the importance of computational capacity in capturing the intricate dependencies inherent in genetic material. This highlights a generalizable trend relevant across domains where large-scale AI methods intersect with complex biological datasets.

As this pioneering technology progresses towards experimental validation, the scientific community stands at the cusp of revolutionary advancements in genome design and synthetic life creation. Evo 2’s ability to generate organellar, prokaryotic, and eukaryotic genomes with nuanced complexity positions it as a harbinger of future integrative bioengineering approaches, merging computational prowess with molecular biology to reshape our understanding of life at its most fundamental level.

In sum, Evo 2 is not merely a predictive model but a transformative generative system that redefines the boundaries of biological sequence design. Its versatility across domains of life and congruence with natural genomic patterns underscore its potential as a universal genome engineering tool, inspiring ongoing research into the applications and implications of artificial genome synthesis.

Subject of Research: Genome modeling and design using generative AI across all domains of life.

Article Title: Genome modelling and design across all domains of life with Evo 2.

Article References:
Brixi, G., Durrant, M.G., Ku, J. et al. Genome modelling and design across all domains of life with Evo 2. Nature (2026). https://doi.org/10.1038/s41586-026-10176-5

DOI: https://doi.org/10.1038/s41586-026-10176-5

ENGRAM operates on the principle of using prime editing, a cutting-edge gene-editing technology, to facilitate insertion events that encode specific cellular behaviors into the genome. The innovative aspect of ENGRAM is its ability to create stable genomic records by allowing these transient signals from CREs to manifest as four-base-pair insertions within the genome. This unique mechanism enables researchers to track the activities of an extensive array of CREs simultaneously. In fact, the multiplexing capability of ENGRAM means that a single experiment can represent the activities of up to 256 distinct CREs, offering an unparalleled level of detail and complexity in examining gene regulation and expression.

This groundbreaking approach harnesses the power of prime editing to ensure that the records of cellular activities are both accurate and enduring. Unlike previous methods that relied on traditional CRISPR systems, which often dealt with unpredictable errors in insertion, ENGRAM leverages the precision of prime editing to create precise and efficiently encoded genetic records. This high fidelity is not just a methodological improvement; it has significant ramifications for our understanding of gene regulation and cellular behavior.

One particularly striking feature of ENGRAM is its integration with a platform known as the DNA Typewriter. This innovative system enables the effective capture of the order in which signals occur, allowing researchers to reconstruct the timing and dynamics of biological processes with unprecedented clarity. By systematically capturing these temporal patterns, ENGRAM enables scientists to discern not only static states of gene expression but also the intricate dance of regulatory activities that govern cellular function.

For researchers eager to dive into the practical applications of ENGRAM, the methodology is accessible, requiring only a fundamental expertise in molecular biology, mammalian cell culture, and DNA sequencing analysis. Collectively, these skills can allow scientists to conduct comprehensive ENGRAM experiments within a span of 5 to 6 weeks. This comparatively short timeline represents a significant step forward, making it feasible for labs to implement cutting-edge genomic recording in routine experimental designs.

The potential applications of ENGRAM reverberate throughout various fields of biological research. From multiplex signal recording to high-throughput CRE screening, the versatility of this system is evident. By enabling simultaneous recording of multiple regulatory elements, ENGRAM paves the way for more complex and informative experiments, where researchers can investigate the interplay and collaboration of multiple CREs in various biological contexts.

Each new milestone achieved through ENGRAM opens avenues for further exploration. One immediate implication is in the realm of developmental biology, where the ability to trace the activity of specific enhancer elements during critical periods of development could provide insights into gene regulation in embryogenesis and organogenesis. Additionally, ENGRAM could prove invaluable in cancer research, facilitating a deeper understanding of how specific regulatory elements contribute to oncogenesis and tumor progression.

Moreover, the capacity to retrospectively analyze these biological records means that scientists could track changes across time, responding to environmental cues or cellular stressors that traditionally have evaded real-time observation. The potential for ENGRAM to act as a molecular historian underscores the innovative spirit of the research community, dedicated to pushing the boundaries of what is possible within biological experimentation.

Yet, despite its remarkable strengths, the ENGRAM system is not without limitations. The design considerations for effective use are nuanced, requiring a keen understanding of both the specific CREs of interest and the cellular context within which they operate. Researchers must carefully consider factors such as the selection of appropriate enhancers and the nature of the prime editing constructs to ensure successful recording outcomes.

In conclusion, the emergence of molecular recording techniques like ENGRAM signifies a profound leap forward in synthetic biology and genomics. With its innovative use of prime editing to establish stable genomic records of regulatory activity, ENGRAM opens the door to a multitude of new research opportunities and paradigm-shifting discoveries. As scientists continue to explore this cutting-edge technology, the potential for ENGRAM to reshape our understanding of biology over time cannot be overstated.

The growing realization of ENGRAM’s capabilities and applications will undoubtedly foster new collaborations and interdisciplinary research initiatives, as experts in various fields seek to harness this innovative method for their own inquiries. The excitement surrounding molecular recording reflects a deeper yearning within the scientific community to understand the complexity of life at a molecular level, further igniting the passion that drives groundbreaking research in synthetic biology.

In summary, ENGRAM represents not just an innovation in genomic technology but a significant stride toward comprehensively deciphering the intricacies of gene regulation, cellular dynamics, and the very essence of biological information processing.

Subject of Research: Enhancer-mediated genomic recording of activity in multiplex

Article Title: Multichannel genomic recording of biological information with ENGRAM

Article References: Nathans, J.F., McDiarmid, T.A., Chen, W. et al. Multichannel genomic recording of biological information with ENGRAM. Nat Protoc (2026). https://doi.org/10.1038/s41596-025-01322-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41596-025-01322-w

Keywords: Molecular recording, synthetic biology, ENGRAM, prime editing, cis-regulatory elements, DNA Typewriter, multiplex signal recording, gene regulation, cellular dynamics

Synthetic biology is rapidly rewriting the blueprint of cellular engineering by using modular genetic components as programmable elements. These genetic switches are designed to toggle genes between active (‘ON’) and inactive (‘OFF’) states, underpinning the development of sophisticated biosensors, cell-based therapies, and efficient biofactories. However, a nagging obstacle has been the so-called “leaky expression” where supposed OFF switches fail to fully suppress gene activity, akin to a faucet that drips despite being turned off. This molecular leakage, though subtle, accumulates over time, burdening cellular metabolism and drastically reducing the reliability and efficacy of genetic circuits.

Professor Kim’s team introduces SUPER as a breakthrough solution that ingeniously circumvents the complexities involved in redesigning genetic parts. Utilizing synthetic small RNAs (sRNAs) as auxiliary regulatory modules, SUPER augments existing genetic switches by selectively suppressing this unwanted basal expression. The approach functions like an additional seal within a leaky faucet, effectively tightening control without necessitating any alteration to the original gene constructs. By simply “upcycling” genetic parts with these sRNA mediators, SUPER amplifies the dynamic control range and boosts circuit stability simultaneously.

The impact of integrating SUPER into natural and synthetic genetic switches has been extraordinary. The platform enabled performance enhancements reaching up to 1,011%, alongside an unprecedented tunable dynamic range exceeding 22,000-fold. Such scalability not only underscores the versatility of SUPER but also highlights its capacity for tailored, context-sensitive genetic regulation—allowing for fine-tuned responses to diverse molecular signals and environmental cues. This precision opens new avenues for engineering customized biological systems without the painstaking trial-and-error typical of genetic redesign.

One of SUPER’s most compelling applications lies in the realm of cellular kill switches, a critical biosafety mechanism designed to eliminate genetically engineered cells when necessary. Historically, residual leakage in kill switch circuits has undermined their effectiveness, leading to incomplete cell elimination and potential survival of resistant mutants. SUPER-enhanced kill switches demonstrated sustained stability for more than a month in live cells, maintaining stringent control over cell viability. Importantly, these systems also integrated multiple environmental inputs, including chemical triggers and temperature shifts, showcasing SUPER’s compatibility with complex regulatory architectures.

Professor Kim emphasized the transformative nature of this upcycling approach: “SUPER enhances both performance and stability across a broad spectrum of genetic devices without the need to modify their core components.” He envisions a future where previously overlooked genetic elements can be harnessed effectively, expanding the utility of synthetic biology in applications ranging from next-generation biotherapeutics to scalable biomanufacturing systems. The SUPER platform, by virtue of its modularity and ease of deployment, stands poised to become a foundational tool for genetic engineers worldwide.

This development emerges against a backdrop of rapid advancements in genomic technologies and functional genomics, where controlling gene expression with exquisite precision is paramount. SUPER’s reliance on small RNAs aligns well with emerging trends in RNA-based regulatory mechanisms, offering a tunable and reversible layer of control that complements existing genomic editing tools. Furthermore, SUPER’s impact extends to biosensor development, where minimizing leakage can drastically improve signal fidelity and responsiveness—key parameters in real-world sensing applications.

The research team meticulously demonstrated SUPER’s operational principle through rigorous testing in model organisms. They illustrated how synthetic sRNAs selectively bind to target mRNA transcripts associated with leaky expression, suppressing translation without disrupting normal gene activation sequences. This finely balanced intervention ensures that the ‘OFF’ state is genuinely silent while preserving swift gene activation upon induction. Such control fidelity is critical for applications requiring tightly controlled gene toggling, including therapeutic gene circuits and metabolic engineering.

SUPER’s engineering simplicity belies its profound functional sophistication. By decoupling control from genetic part modification, it dramatically reduces the time and resource investment typically required for circuit optimization. This design philosophy aligns with the broader synthetic biology ethos of modularity and standardization, allowing genetic parts to be reliably repurposed and integrated across diverse platforms. The modular sRNA controllers can be designed and scaled independently, furnishing synthetic biologists a highly customizable toolkit for complex gene regulatory networks.

The implications of these findings extend beyond laboratory research. In clinical settings, where engineered cells serve as living therapeutics, the stability and predictability conferred by SUPER can greatly enhance safety profiles and therapeutic efficacy. Likewise, in industrial biotechnology, where microbial cell factories produce valuable biomolecules, minimizing leakage curbs metabolic waste and enhances yield, directly impacting cost-efficiency and sustainability. As bioengineering increasingly intersects with environmental and public health domains, such robust control mechanisms will be essential.

Funded by a consortium of Korean scientific and governmental bodies, including the Korea Health Industry Development Institute and the Ministry of Agriculture, Food and Rural Affairs, this work underscores the growing global leadership in synthetic biology innovation emerging from Asia. The collaborative effort involving multidisciplinary expertise in molecular biology, genetics, and bioengineering highlights the integrative approach necessary to solve complex biological challenges. It also sets a precedent for future endeavors seeking to harness synthetic regulatory modules to elevate genetic circuit design.

In conclusion, the SUPER platform represents a paradigm shift in genetic engineering, providing a versatile, efficient, and broadly applicable solution to the perennial problem of gene expression leakage. By leveraging synthetic small RNAs as modular add-ons, SUPER empowers scientists to achieve unprecedented control over gene regulation without redesigning fundamental genetic parts. This advancement not only deepens our understanding of genetic control mechanisms but also propels the synthetic biology field toward more reliable and scalable applications in medicine, industry, and environmental management.

Subject of Research: Synthetic genetic regulation and gene expression control using synthetic small RNA modules.

Article Title: SUPER: Upcycling Genetic Parts for Precise Gene Expression Control, Leakage Minimization, and Genetic Circuit Stability

News Publication Date: 15-Dec-2025

Web References:
DOI: 10.1002/advs.202514653

Image Credits: POSTECH

Keywords: Synthetic biology, gene regulation, small RNAs, genetic circuits, gene expression control, biosensors, cellular kill switches, genetic stability, biotechnology, molecular biology, functional genomics, RNA sequencing

Natural organisms primarily rely on a limited number of metabolic routes to assimilate formate, but these pathways are often inefficient and confined to microbial species that are genetically challenging to manipulate. Conventional formate assimilation typically yields limited production efficiencies, hampering industrial-scale implementations for C1 bioconversion. Seeking to overcome these inherent challenges, the research team embarked on establishing an entirely synthetic formate assimilation pathway that operates outside cellular confines, thus offering greater control, flexibility, and scalability.

The ReForm pathway is an intricate six-step enzymatic sequence composed of five engineered enzymes innovatively repurposed to catalyze reactions not naturally observed in biology. These enzymes form a cascade that successively converts formate into acetyl-CoA, a universally essential metabolic intermediate that feeds into numerous biosynthetic and energy-generating pathways. By harnessing acetyl-CoA as the product, ReForm broadens the spectrum of possible downstream biochemical transformations, potentially enabling the sustainable production of fuels, polymers, and pharmaceuticals from CO2-derived feedstocks.

To assemble this synthetic cascade, researchers performed an exhaustive search and screening process, examining a library of 66 enzyme candidates sourced from diverse prokaryotic and eukaryotic organisms. This exhaustive hunt identified enzymes exhibiting the desired catalytic activities, substrate specificities, and kinetic properties amenable to integration into a synthetic setting. The team then embarked on an iterative engineering campaign, creating and characterizing an extraordinary number of mutants—totaling over 3,100 sequence-defined enzyme variants—tailoring each enzyme’s performance through precise amino acid substitutions.

This iterative protein engineering enabled fine-tuning of enzyme specificity, stability, and catalytic efficiency, essential for achieving high overall pathway throughput. Modulating enzyme loadings and cofactor concentrations was also critical in optimizing the metabolic flux through the ReForm pathway, ensuring balanced reaction kinetics and avoiding bottlenecks. By systematically adjusting these parameters, the researchers significantly enhanced the production yield and rate of malate, chosen as a model end product indicative of acetyl-CoA availability and pathway functionality.

Remarkably, the versatility of ReForm was demonstrated by its ability to accept not only formate but also related C1 substrates such as formaldehyde and methanol. These substrates are also accessible via various synthetic or biological routes from CO2, underscoring the pathway’s adaptability for diverse feedstock streams. This flexibility suggests that ReForm could be integrated with multiple upstream processes, including electrochemical and photochemical CO2 reduction, to form a seamless carbon capture and conversion platform.

The electrochemical reduction of CO2 to formate is gaining traction as a promising method to capture ambient carbon dioxide and generate renewable chemicals. However, converting electrochemically produced formate into more complex and biologically relevant molecules has been a critical bottleneck. ReForm addresses this challenge directly by providing an enzymatic means to upgrade formate efficiently without the need for living cells, which often require complex growth conditions and face product toxicity issues.

Operating in a cell-free environment, ReForm avoids metabolic regulation constraints imposed by cellular homeostasis, allowing for precise control over reaction conditions and enabling the deployment of non-natural enzymatic reactions. This synthetic approach circumvents the genetic roadblocks found in microbes, which are notoriously difficult to engineer for C1 bioconversion. Moreover, the modular nature of ReForm facilitates integration with other synthetic pathways, opening avenues for modular bioprocess design adaptable to various industrial requirements.

The implications of creating such a synthetic formate assimilation pathway extend beyond biomanufacturing. It paves the way towards developing a formate-based bioeconomy, leveraging the abundant and renewable nature of CO2 as a carbon source. With global emphasis on decarbonization and sustainable production of chemicals, pathways like ReForm could underpin future carbon-neutral manufacturing systems, reducing dependence on fossil fuels and mitigating greenhouse gas emissions.

Furthermore, the successful demonstration of ReForm logic invites exploration into other synthetic pathways for C1 and multi-carbon substrate conversion. It showcases the power of combining enzyme discovery, protein engineering, and metabolic pathway assembly optimization, highlighting how cell-free synthetic biology can accelerate the development of new biocatalytic routes that natural evolution has yet to produce.

Looking ahead, challenges remain in scaling up such cell-free enzymatic systems and achieving cost-competitiveness at industrial scales. However, the advances presented here lay a solid foundation for future efforts aimed at integrating synthetic biochemical pathways with renewable energy inputs. Through continued engineering and optimization, ReForm-based biomanufacturing platforms could soon be tailored to sustainably produce a vast array of chemicals, pharmaceuticals, and biofuels.

This research also emphasizes the critical role of multidisciplinary collaboration, blending expertise from enzymology, synthetic biology, chemical engineering, and electrochemistry. By exploiting synergies across these fields, the team has demonstrated a pioneering strategy towards merging renewable energy conversion (electrochemical CO2 reduction) with biological catalysis, fundamentally reimagining carbon utilization for a sustainable future.

Beyond the immediate biochemical achievements, ReForm’s development heralds a paradigm shift in how we conceptualize and implement carbon recycling technologies. Instead of relying solely on engineering living systems hampered by evolutionary constraints, the adoption of synthetic, cell-free enzymatic cascades represents a flexible, programmable platform capable of rapid iteration and adaptation. This capability has profound implications for accelerating innovation cycles in industrial biotechnology.

Moreover, the successful design and validation of ReForm provide key proof-of-concept validation for the use of non-natural enzymatic reactions within synthetic pathways. This expands the toolkit available for designing carbon fixation and assimilation routes, potentially overcoming natural thermodynamic and kinetic limitations. It also encourages future researchers to consider unconventional enzymatic transformations when designing synthetic pathways, broadening the horizon of biocatalytic possibilities.

In summary, the ReForm pathway fundamentally transforms the landscape of C1 bioconversion by introducing an efficient, cell-free synthetic route to upgrade formate—derived sustainably from electrochemically reduced CO2—into acetyl-CoA. This breakthrough promises to catalyze innovations in sustainable chemical production and carbon recycling, ushering in a new era where synthetic biology and renewable energy converge synergistically to address climate and resource challenges.

The study demonstrates that leveraging a diverse enzyme repository, coupled with exhaustive protein engineering and reaction tuning, can unlock unprecedented metabolic capabilities. Such approaches empower the design of tailor-made biochemical pathways that surpass natural constraints, offering robust platforms for future biomanufacturing and synthetic carbon fixation technologies. ReForm represents a milestone on the path towards a circular carbon economy, where CO2 is not a pollutant, but a vital raw material for a sustainable future.

Subject of Research: Synthetic biochemical pathways for formate assimilation and upgrading derived from electrochemical CO2 reduction.

Article Title: A synthetic cell-free pathway for biocatalytic upgrading of formate from electrochemically reduced CO2.

Article References:
Landwehr, G.M., Vogeli, B., Tian, C. et al. A synthetic cell-free pathway for biocatalytic upgrading of formate from electrochemically reduced CO2. Nat Chem Eng (2025). https://doi.org/10.1038/s44286-025-00315-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s44286-025-00315-6

At its core, this innovation employs a powerful genomic sequence model called Evo, which was trained on an unprecedented scale of prokaryotic genomic data. Unlike protein design that typically focuses on narrow regions of sequence space or requires laborious structural predictions, Evo taps into the latent functional information encoded not just in isolated gene sequences but within the broader genomic neighborhoods they inhabit. This contextual understanding enables the model to generate de novo gene variants that successfully encode desired functions at experimental success rates ranging between 17 to 50 percent after testing relatively few variants. Such rates surpass many existing protein engineering methodologies, highlighting the potency of conditioning on genomic context.

Remarkably, many designed proteins from this approach display no significant sequence similarity to any known proteins, including those with related functions. This unprecedented novelty blurs the line between de novo protein design and evolution-guided diversification, presenting an ‘existence proof’ that these language models can generalize far beyond the natural sequence repertoires catalogued in biological databases. It opens new avenues to design proteins with unprecedented functional diversity, drawing upon evolutionary principles encoded in genome architecture yet generating sequences never before seen in nature.

What sets semantic design apart from prior techniques is its fundamentally different paradigm for creating functional biological molecules. It does not require any task-specific fine-tuning that risks overfitting to known examples, nor does it rely on natural language prompts derived from existing knowledge bases. Instead, semantic design excavates the rich reservoir of functional diversity hidden within genomic sequences and their ecological and evolutionary contexts. This method can thus access proteins and functions that have not yet been characterized by science, catering to a realm of biological utility beyond current annotations or hypotheses.

A striking demonstration of this technique’s versatility is provided through the generation of novel antitoxins that imply a broader compatibility across diverse toxin–antitoxin systems than previously reported, as well as an anti-CRISPR protein linked to a protein family with a different presumed function. These findings exemplify how semantic design can reveal cross-functional relationships and hidden compatibilities that defy conventional wisdom in molecular biology. It also underscores the advantage of bypassing mechanistic or structural assumptions, as filtering based on predicted structure quality would have discarded many of these successfully designed proteins.

Semantic design emerges not as a replacement but as a complementary strategy alongside classical protein engineering and directed evolution. Its ability to explore vast synthetic sequence space beyond the constraints of well-characterized natural genes presents an exciting toolkit for rational design and innovation. Particularly for functions like anti-CRISPR activity, where multiple structural and mechanistic paths exist, genomic conditioning can selectively guide design towards functional outputs less accessible to traditional approaches.

Crucially, although Evo 1.5 was the model employed for these landmark achievements, the semantic design framework is agnostic to the particular model architecture or training dataset. Any sufficiently trained language model on prokaryotic or phage genomes can be integrated into this framework. As model capabilities improve and our understanding of gene synteny—the relative order and arrangement of genes in genomes—deepens, the power and scope of semantic design are expected to grow commensurately.

The traditional paradigm in biological sequence discovery relies heavily on the concept of “guilt by association,” where hypotheses about gene function are inferred from evolutionary conservation and similarity across species. This constraint limits exploration to the slowly accumulated diversity shaped over billions of years of life’s history. By contrast, semantic design enables a rapid and expansive sampling of synthetic sequences tailored to specific biological systems. To democratize access to this unprecedented resource, the team has released SynGenome, a publicly available database containing over 120 billion base pairs of AI-generated genomic sequences, providing a valuable platform for researchers worldwide to uncover novel synthetic biological parts.

Despite its transformative potential, semantic design faces inherent challenges. Autoregressive sequence generation methods sometimes produce repetitive or hallucinated sequences that appear plausible but lack true functionality. Moreover, genes generated through contextual conditioning may encode regulatory elements rather than the direct functional proteins initially targeted, necessitating rigorous in silico screening and empirical validation. The approach is currently most effective in prokaryotic systems, reflecting the genomic structures and functional architectures captured by training data, and extending semantic design to eukaryotic organisms will require novel strategies attuned to their complex genome organization.

Looking forward, the rapidly growing corpus of genomic data, coupled with advances in language model architectures and inference algorithms, promises to elevate semantic design to new heights. More sophisticated models that can generate entire multi-component biological systems, as demonstrated with toxin–antitoxin pairs, foreshadow the ability to engineer complex synthetic circuits, metabolic pathways, or even whole genomes. These capabilities could accelerate the creation of bespoke living systems tailored for medicine, industry, and environmental applications.

Beyond mere synthetic biology, semantic design opens a window into an expanded biological reality, uncovering sequences and functions veiled from natural observation. This synthetic genomic space is a frontier ripe for discovery, with the potential to reveal new molecular machines and evolutionary principles. By integrating rich semantic information encoded in genomes with computational creativity, scientists are reshaping our capacity to design life itself, heralding a new epoch of bioengineering that transcends the limits of natural evolution.

In essence, this work marks a profound shift in how we conceive and manipulate the building blocks of life. It boldly illustrates that language models trained on biological sequences are not only tools for data analysis but are potent generative engines capable of inventing functional, novel genes and proteins. As the field advances, semantic design could fundamentally alter the trajectory of biotechnology, synthetic biology, and our understanding of the molecular basis of life.

Subject of Research:
Design of functional de novo genes using genomic language models trained on prokaryotic DNA sequences.

Article Title:
Semantic design of functional de novo genes from a genomic language model.

Article References:
Merchant, A.T., King, S.H., Nguyen, E. et al. Semantic design of functional de novo genes from a genomic language model. Nature (2025). https://doi.org/10.1038/s41586-025-09749-7

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41586-025-09749-7

Bacteriophages, or phages, are viruses that infect bacteria and have been of interest for over a century due to their potential therapeutic uses. However, the complexity and natural variability of phage genomes have historically hindered efforts to manipulate them systematically. Professor Hatfull’s team has overcome these challenges by synthesizing complete phage genomes from scratch, enabling researchers to customize their genetic makeup according to precise experimental requirements. This capability marks a transformative leap in the capacity to dissect phage function and regulation at an unprecedented level of detail.

The synthetic construction of phage genomes permits scientists to interrogate fundamental biological questions that have long remained elusive. For example, among phages that contain upwards of 100 genes, it has been unclear which genes are essential for infectivity, replication, or host interaction and which are redundant or auxiliary. With the ability to design and assemble synthetic phage genomes devoid of certain genes, researchers can now systematically delete or replace individual genetic elements and observe the resultant effects on phage viability and efficacy. This experimental flexibility accelerates discovery, paving the way to understand gene regulation and interaction networks within these viruses.

For their landmark study, Hatfull and his colleagues focused on mycobacteriophages—phages that infect mycobacteria, a genus that includes significant human pathogens such as Mycobacterium tuberculosis and Mycobacterium leprae, responsible for tuberculosis and leprosy respectively. By synthesizing and assembling genomes representative of two naturally occurring high G+C content mycobacteriophages, the team demonstrated that bespoke phage genomes could be “rebooted” or activated to create functioning viral particles in the laboratory. This synthetic rebooting confirms that phages retain their bactericidal properties even when entirely constructed from synthetic DNA.

The practical implications of this breakthrough extend deeply into the field of antimicrobial therapy. Antibiotic resistance poses a grave and escalating threat worldwide, with superbugs rendering many conventional treatments ineffective. Engineered phages, tailored to precisely target specific bacterial strains, offer a potent alternative to broad-spectrum antibiotics. The synthetic genome technique enables the design of phages with enhanced efficacy, specificity, and the ability to evade bacterial defense systems, potentially revitalizing therapeutic strategies against resistant infections.

Moreover, the ability to assemble artificial genomes brings synthetic biology principles into virology, enabling the design of novel phage variants with properties not found in nature. Researchers are no longer restricted to naturally occurring genetic combinations; they can now imagine and realize entirely new genomes that optimize infection mechanics, host range, and safety profiles. The phrase used by Professor Hatfull, “the sky’s the limit,” reflects the vast potential unlocked by this technology to create phages of significant therapeutic and research value.

This ambitious project was carried out in collaboration with two pioneering institutions in biotechnology: Ansa Biotech and New England Biolabs. These collaborations combined cutting-edge DNA synthesis and assembly technologies with decades of expertise in phage biology and mycobacterial research. The integration of synthetic genomics and classical phage biology methodologies ensured that the synthetic genomes were both functional and representative of complex natural phage systems, making this study a model for future interdisciplinary research.

Scaling synthetic phage engineering could also contribute to faster and more effective responses against emerging bacterial threats. By enabling rapid prototyping of phages with tailored genomes, laboratories can adapt to new bacterial variants or outbreaks more swiftly than ever before. Unlike traditional antibiotic development, which can take years, synthetic phage design and validation could be accelerated substantially using this platform, allowing for more agile public health interventions.

Furthermore, the detailed mechanistic insights gained from studying synthetic phage genomes could inform bioengineering efforts to enhance phage stability and delivery in clinical settings. Synthetic manipulation may optimize viral capsid structures, DNA packaging signals, or host recognition receptors, potentially leading to phages that remain active longer in the human body or target hard-to-reach bacterial reservoirs. This could vastly improve the therapeutic index of phage treatment, increasing its viability as a frontline medical tool.

Scientifically, this work also addresses fundamental questions about the modularity and evolution of viral genomes. Through synthetic assembly, researchers can experiment with genome rearrangements, gene insertions from other organisms, or even the creation of chimeric phages. Such experiments could reveal unknown genetic interactions and evolutionary constraints while expanding the molecular toolkit available for viral engineering.

The findings from this study will be published in the prestigious Proceedings of the National Academy of Sciences (PNAS), emphasizing the high impact and relevance of this research to multiple scientific disciplines. Importantly, the project is funded by the NIH and the Howard Hughes Medical Institute, highlighting its critical importance and potential to transform clinical microbiology and synthetic biology.

As the scientific community digests this revolutionary approach, the knock-on effects are expected to ripple across why we study viruses, treat bacterial diseases, and engineer synthetic biological systems. The innovative synthesis and rebooting of phages represent a milestone in both basic and applied research, providing a flexible platform for future innovations that could dramatically reshape bacterial infection management and further advance synthetic genomics.

Contacts for media inquiries and further information about this groundbreaking research are available at the University of Pittsburgh, ensuring that the exciting discoveries will be communicated broadly and promptly as developments progress.

Subject of Research: Cells
Article Title: Genome synthesis, assembly, and rebooting of therapeutically useful high G+C% mycobacteriophages
News Publication Date: 14-Nov-2025
Web References: 10.1073/pnas.2523871122
Keywords: Bacteriophages, Antibiotic resistance, Drug resistance, Artificial genomes, Synthetic biology